ABLE and Biotechnology Industry in India are focused on achieving the $100 billion BioEconomy target by 2025. The current industry size is about $42 billion.
BioEconomy India Conclave on Oct 4-5, 2018 in Pune will focus on the theme: Strategies for the $100 Billion BioEconomy.
BioEconomy India Conclave 2018 will identify high growth segments, potential new areas and list the requirement from policy makers, regulators, infrastructure providers, funding agencies and HR institutions to prepare for this future. This 2-day conference will have Special Sessions, Key Notes and Networking.
Venue : Indian Institute of Science Education and Research (IISER), Dr Homi Bhabha Road, Pashan, Pune 411 008
Date : Oct 4-5, 2018.
The growing demand for food from a growing population is creating the need for sustainable practices in agriculture. New innovations in Plant Nutrition will play a key role in ensuring that growers can sustainably meet future food demands while remaining economically productive. These innovations include advances in biologically sourced inputs such as agri biology and biostimulants that can make existing practices more effect.
Biosimilars can target drugs worth $ 80 billion annual sales going off patent in the next few years. The new Biosimilar Policy guidelines issued in 2016 makes a strong case for more activity in this sector.
New generation energy sources is very much essential in Indian and global context. The available renewable sources have to be optimized to give maximum biofuel returns. As the fifth largest energy consumer in the world, India additionally provides a good market for biofuels. This segment offers potential opportunities to decrease the nation’s dependence on foreign energy imports.
The advent of the latest inventions and technologies in accurate detection and quicker screening, and the prolific growth in genetic testing have driven the revenues of the Indian molecular diagnostics market in recent years. Demand for genomic sequencing services is also rapidly rising, particularly for plant genomics. This will open a bigger opportunity area for budding entrepreneurs.
In a recent survey, domestic API manufacturers, finished dose manufacturers and CDMOs were asked what factors are holding back biotechnology and manufacturing in India.
Of the 433 respondents in the 'CPhI India Pharma Insights survey,’ 38% said there has not been enough government support, while a further 33% placed the problem with a lack of early stage funding from angel investors. Lack of biomanufacturing expertise in the country was also cited as a problem.
India has laid down a strategic roadmap for creating an optimal ecosystem that encourages bio-manufacturing through industry-friendly policies, smart regulations, world class infrastructure and relevant skill development initiatives.
Though, globally research in synthetic biology and its application are on high priority, India is lagging behind in this field of research and an urgent need arises to promote and accelerate the synthetic biology research in India. It holds a key to solve many challenges such as food & energy scarcity and drugs against incurable diseases. Thus, initiative should be taken by Indian scientists to design, construct and characterize the novel synthetic genetic parts, devices and circuits for reprogramming of cellular machinery with predictive function. These engineered organisms should be robust, fast, and efficient for production of value-added products for controlling the diseases. The community effort is needed to promote and accelerate the synthetic biology research in India so that India is globally competitive.
CRISPR, the gene-editing tool, is emerging as a highly promising technology of the future in agriculture. The latest endorsement has come from a new book, “SOONISH: Ten Emerging Technologies That’ll Improve and/or Ruin Everything” by science writer couple, Kelly and Zach Weinersmith in the US. India is yet to tap the benefits of this technology in agriculture in a big way. It is high time, India’s policy makers in agriculture and biotechnology, invest more time and resources to harness the potential of another technology of the future: CRISPR.
ABLE has formed a Mentor Cell and the event is an opportunity to mentor startups and others by the experienced member.